Alithea Genomics

Alithea Genomics, a Lausanne-based RNA sequencing company, has secured CHF 3 million ($3.9 million) in its seed financing round, totaling CHF 6.9 million ($8.9 million). The round was led by Genku Ventures, with participation from Novalis Biotech and Zürcher Kantonalbank. The funding will accelerate the commercialization of its 1,536-well Mercurius drug-seq kits and support AI initiatives. The company aims to simplify RNA data generation for drug development, enhancing research efficiency.

Alithea Genomics, a Swiss biotech startup, has secured CHF 6.9 million ($8.9 million) in seed funding to enhance its RNA sequencing technology, making large-scale transcriptomics more accessible for drug discovery and toxicology research. The funding round included an additional CHF 3 million ($3.9 million) led by Genku Ventures, with participation from Novalis Biotech and others. The investment will accelerate the commercialization of their 1536-well Mercurius drug-seq kits, enabling scientists to process up to 1,536 samples simultaneously, thus facilitating early drug screening.